Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Apimeds Pharmaceuticals US, Inc. subsidiary MindWave Innovations Inc. entered a two-year agreement with BlockAssure Inc. on October 4, 2026 to build and operate AssureChain for on-chain insurance and reinsurance, with quarterly development fees and 20% of AssureCoin.
Apimeds Pharmaceuticals US, Inc. appointed Eric Sherb as Chief Financial Officer effective October 1, 2026, succeeding Erick Frim’s immediate resignation as Interim Chief Financial Officer on September 29, 2026; Sherb’s base salary is $60,000 per year.
Apimeds Pharmaceuticals US, Inc. effected a one-for-ten reverse stock split effective as of 12:01 a.m. Eastern Time on July 24, 2026, reducing common stock par value from $0.01 per share to $0.001 per share.
